Clínica de Marly S.A. (BVC:MARLY)
Colombia · Delayed Price · Currency is COP 8,500.00
0.00 (0.00%)
At close: Aug 21, 2026
Clínica de Marly Income Statement
Financials in millions COP. Fiscal year is January - December.
Millions COP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 451,971 | 435,862 | 413,169 | 362,905 | 321,343 | 278,599 | |
Revenue Growth | 5.43% | 5.49% | 13.85% | 12.93% | 15.34% | 32.81% |
Cost of Revenue | 284,728 | 274,002 | 256,982 | 231,992 | 208,407 | 178,364 |
Gross Profit | 167,243 | 161,860 | 156,187 | 130,913 | 112,935 | 100,234 |
Selling, General & Admin | 59,285 | 43,095 | 40,774 | 36,964 | 33,870 | 28,018 |
Amortization of Goodwill & Intangibles | 593.18 | 1,056 | 904.1 | 849.82 | 492.11 | 401.94 |
Other Operating Expenses | 2,633 | 6,796 | 5,608 | 5,453 | 3,985 | 3,091 |
Operating Expenses | 64,983 | 55,871 | 52,087 | 47,948 | 43,641 | 36,557 |
Operating Income | 102,259 | 105,989 | 104,100 | 82,965 | 69,294 | 63,678 |
Interest Expense | -3,747 | -213.66 | -1,364 | -2,324 | -2,206 | -1,608 |
Interest & Investment Income | 10,323 | 20,611 | 16,025 | 12,491 | 5,805 | 1,749 |
Earnings From Equity Investments | 40,211 | 40,025 | 36,628 | 21,135 | 19,381 | 18,419 |
Currency Exchange Gain (Loss) | -1,643 | -3,212 | 2,345 | -3,530 | 2,616 | 2,421 |
Other Non Operating Income (Expenses) | -7,995 | -24,469 | -21,831 | -8,019 | -12,403 | -12,456 |
EBT Excluding Unusual Items | 139,409 | 138,730 | 135,903 | 102,718 | 82,487 | 72,203 |
Gain (Loss) on Sale of Investments | 183.41 | 298.33 | 233.45 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 26.91 |
Asset Writedown | -4,240 | -10,635 | -8,460 | -7,413 | -550.3 | -1,958 |
Pretax Income | 135,353 | 128,394 | 127,676 | 95,306 | 81,936 | 70,271 |
Income Tax Expense | 40,929 | 40,362 | 38,820 | 30,536 | 26,642 | 20,467 |
Earnings From Continuing Operations | 94,424 | 88,032 | 88,856 | 64,770 | 55,295 | 49,804 |
Minority Interest in Earnings | -699.09 | -597.59 | -1,121 | -89.46 | -713.74 | -830.06 |
Net Income | 93,725 | 87,435 | 87,735 | 64,681 | 54,581 | 48,974 |
Net Income to Common | 93,725 | 87,435 | 87,735 | 64,681 | 54,581 | 48,974 |
Net Income Growth | 4.54% | -0.34% | 35.64% | 18.50% | 11.45% | 78.41% |
Shares Outstanding (Basic) | - | - | - | 11 | 11 | 11 |
Shares Outstanding (Diluted) | - | - | - | 11 | 11 | 11 |
Shares Change | - | - | - | - | - | - |
EPS (Basic) | - | - | - | 6057.41 | 5111.57 | 4586.50 |
EPS (Diluted) | - | - | - | 6057.41 | 5111.57 | 4586.50 |
EPS Growth | - | - | - | 18.50% | 11.45% | 78.41% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 16,473 | 31,264 | -422.9 | 23,300 | 27,495 | 16,504 |
Free Cash Flow Per Share | - | - | - | 2182.04 | 2574.90 | 1545.65 |
Dividend Per Share | - | - | 1596.000 | 1200.000 | 696.000 | 564.000 |
Dividend Growth | - | - | 33.00% | 72.41% | 23.40% | - |
Gross Margin | 37.00% | 37.14% | 37.80% | 36.07% | 35.14% | 35.98% |
Operating Margin | 22.63% | 24.32% | 25.20% | 22.86% | 21.56% | 22.86% |
Profit Margin | 20.74% | 20.06% | 21.23% | 17.82% | 16.98% | 17.58% |
Free Cash Flow Margin | 3.65% | 7.17% | -0.10% | 6.42% | 8.56% | 5.92% |
EBITDA | 108,252 | 111,900 | 109,736 | 88,446 | 75,033 | 69,075 |
EBITDA Margin | 23.95% | 25.67% | 26.56% | 24.37% | 23.35% | 24.79% |
D&A For EBITDA | 5,992 | 5,910 | 5,635 | 5,480 | 5,739 | 5,397 |
EBIT | 102,259 | 105,989 | 104,100 | 82,965 | 69,294 | 63,678 |
EBIT Margin | 22.63% | 24.32% | 25.20% | 22.86% | 21.56% | 22.86% |
Effective Tax Rate | 30.24% | 31.44% | 30.40% | 32.04% | 32.52% | 29.13% |